TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
6/13/23 16:41 | 6/9/23 | AVTX | Avalo Therapeutics, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Sullivan Christopher Ryan | MD | O | CFO | P | 2 | 3.42 | 0 | 1 | 68 | 1 | D | ||||||||||||||
12/14/21 17:17 | 12/10/21 | AVTX | Avalo Therapeutics, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Sullivan Christopher Ryan | MD | O | Chief Ac | P | 1 | 1.57 | 0 | 1 | 12 | 9 | D | ||||||||||||||
12/14/20 16:12 | 12/10/20 | CERC | Cerecor Inc. | DE | Health | Drug | Pharmaceutical Preparations | Sullivan Christopher Ryan | MD | O | Interim | P | 12 | 2.28 | 0 | 5 | 172 | 8 | D | ||||||||||||||
6/11/20 21:08 | 6/10/20 | CERC | Cerecor Inc. | DE | Health | Drug | Pharmaceutical Preparations | Sullivan Christopher Ryan | MD | O | Interim | P | 7 | 2.28 | 0 | 3 | New | 3 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |